Seeking Alpha

Cell Therapeutics rallies on NICE nod for Pixuvri

  • Cell Therapeutics (CTIC) rises 3% premarket.
  • U.K. cost gatekeeper NICE has issued a positive final draft opinion on Pixuvri.
  • The regulator "recommends funding the treatment as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma," the company says.
  • Here's CEO James Bianco: "[This] means that physicians in England and Wales now have access to the only approved therapy for their patients with aggressive B-cell NHL in the third- and fourth-line salvage setting." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs